E-ISSN 2534-9821
 
2023, Vol: 7, Issue: 12
7 / 12Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Copyright Transfer Form

Case Report
Online Published: 27 Dec 2022
 


Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer

Gary W Takahashi.


Abstract
An elderly patient with metastatic lung adenocarcinoma presented with excessive bruising and persistent oozing several months after treatment with pembrolizumab, an immune checkpoint inhibitor. The cause of this hemostatic deficiency was identified as an inhibitor to factor VIII. Therapy with FEIBA (factor VIII inhibitor bypass activity), corticosteroids and immune gamma globulin resulted in clinically adequate improvement, but incomplete normalization of hemostatic parameters. Durable and complete restoration of aPTT and factor VIII activity occurred after subsequent treatment with rituximab, and supports its use as definitive therapy for acquired hemophilia resulting from the use of immune checkpoint inhibitor monoclonal antibodies.

Key words: acquired hemophilia, pembrolizumab, acquired factor VIII inhibitor, coagulopathy


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Gary W Takahashi
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Gary W Takahashi|. Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. Int J Med Rev Case Rep. 2022; 6(20): 1-3. doi:10.5455/IJMRCR.172-1661296750

Web Style

Gary W Takahashi|. Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. https://www.mdpub.net/?mno=108642 [Access: April 02, 2025]. doi:10.5455/IJMRCR.172-1661296750

AMA (American Medical Association) Style

Gary W Takahashi|. Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. Int J Med Rev Case Rep. 2022; 6(20): 1-3. doi:10.5455/IJMRCR.172-1661296750


Vancouver/ICMJE Style

Gary W Takahashi|. Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. Int J Med Rev Case Rep. (2022), [cited April 02, 2025]; 6(20): 1-3. doi:10.5455/IJMRCR.172-1661296750


Harvard Style

Gary W Takahashi| (2022) Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. Int J Med Rev Case Rep, 6 (20), 1-3. doi:10.5455/IJMRCR.172-1661296750


Turabian Style

Gary W Takahashi|. 2022. Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. International Journal of Medical Reviews and Case Reports, 6 (20), 1-3. doi:10.5455/IJMRCR.172-1661296750


Chicago Style

Gary W Takahashi|. "Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer." International Journal of Medical Reviews and Case Reports 6 (2022), 1-3. doi:10.5455/IJMRCR.172-1661296750


MLA (The Modern Language Association) Style

Gary W Takahashi|. "Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer." International Journal of Medical Reviews and Case Reports 6.20 (2022), 1-3. Print. doi:10.5455/IJMRCR.172-1661296750


APA (American Psychological Association) Style

Gary W Takahashi| (2022) Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. International Journal of Medical Reviews and Case Reports, 6 (20), 1-3. doi:10.5455/IJMRCR.172-1661296750


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About International Journal of Medical Reviews and Case Reports

International Journal of Medical Reviews and Case Reports  (Int J Med Rev Case Rep)ISSN: 2534-9821The International Journal of Medical Reviews and Ca ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31,  Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press. 

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500